Business Context and Reporting Period
This Form 8-K is filed by TransBiotec, Inc. (not SOBR Safe, Inc., despite the metadata reference) for the reporting period ending October 25, 2019, with a signature date of November 18, 2019. The filing primarily addresses significant changes in corporate governance, the appointment of new executive officers, and the issuance of unregistered equity securities under the company's 2019 Equity Incentive Plan.
Key Financial Metrics and Equity Issuances
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it details significant equity compensation arrangements and potential dilution:
- CEO Compensation (Kevin Moore): 800,000 shares of common stock per month until the IDTEC Transaction closes (or Jan 31, 2020); annual base salary of $213,000 post-closing; options to acquire 35,200,000 shares at $0.00792/share.
- CRO Compensation (David Gandini): Annual base salary of $185,000; options to acquire 32,000,000 shares at $0.00792/share (including 8,000,000 pre-vesting shares); potential entitlement to 1,000,000 shares upon closing of the IDTEC Transaction.
- Other Grants: Options granted to officers, directors, and consultants totaling approximately 8,800,000 shares (Bennington, Noceti, Graham, and four non-affiliated entities) at an exercise price of $0.00792/share.
- Exercise Price: All options were priced at $0.00792, representing 110% of the fair market value on October 25, 2019.
Material Changes Versus Prior Period
The filing reports a complete restructuring of the company's top leadership and board composition:
- Executive Leadership: Charles Bennington resigned as Chief Executive Officer (CEO) but remains President, Secretary, and Board member. Kevin Moore was appointed CEO. David Gandini was appointed Chief Revenue Officer (CRO).
- Board of Directors: Daljit Khangura and Devadatt Mishal resigned from the Board. Gary Graham was appointed to the Board.
- Corporate Governance: The Board approved Amended and Restated Bylaws, replacing the 2007 bylaws from the company's previous incarnation as Imagine Media, Ltd.
- Equity Plan: The 2019 Equity Incentive Plan became effective on October 24, 2019, following shareholder approval, enabling the recent grants.
Outlook, Risks, and Contingencies
Management commentary and future outlook are heavily contingent on a pending transaction:
- IDTEC Transaction Contingency: The employment agreements for the new CEO and CRO are conditional. If the Asset Purchase Agreement with IDTEC, LLC does not close by January 31, 2020, the employment of both executives will terminate immediately.
- Equity Dilution Risk: The filing discloses the issuance of unregistered securities totaling over 76 million shares in options and potential stock grants to key personnel, which may significantly impact the capital structure.
- Regulatory Compliance: All equity issuances were exempt from registration under Section 4(a)(2) of the Securities Act of 1933, relying on the recipients being sophisticated investors or insiders.
Investor Verification Checklist
- Verify the status and closing timeline of the IDTEC Transaction, as executive retention depends on its completion by January 31, 2020.
- Confirm the total authorized share count and the impact of the 76+ million option grants on existing shareholder dilution.
- Review the full text of the Employment Agreements (Exhibits 10.2 and 10.3) for specific termination clauses and performance metrics.
- Check for any subsequent filings regarding the resignation of former directors and the integration of the new management team.
- Clarify the company's current cash position and liquidity, as this filing does not disclose financial statements.